Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Grass pollen allergoids are chemically modified allergen extracts derived from grass species such as Phleum pratense (Timothy grass) and Dactylis glomerata (Orchard grass), primarily utilized in allergen-specific immunotherapy (AIT). The modification process, typically involving polymerization with agents like glutaraldehyde or formaldehyde, alters the molecular structure of the allergens to reduce their IgE-binding capacity while maintaining their immunogenicity. This allows for the administration of higher allergen doses with a reduced risk of immediate systemic allergic reactions compared to native extracts. Biologically, the source allergens often include proteins from the beta-expansin family (Group 1 allergens) and ribonuclease-like proteins (Group 5 allergens), which naturally play roles in plant cell wall extension and pollen germination. In clinical practice, grass pollen allergoids are used to treat allergic rhinitis and allergic asthma by restoring immune tolerance. These agents target the immune system by modulating the T-cell response, inducing regulatory T cells, and promoting a shift from pro-inflammatory Th2 responses to tolerogenic profiles. This shift results in the production of allergen-specific blocking antibodies, particularly IgG4, which inhibit the IgE-mediated activation of mast cells and basophils. While effective for long-term disease modification, safety challenges include the potential for anaphylaxis and interactions with drugs such as beta-blockers or MAOIs, which can impede the effectiveness of emergency epinephrine treatment.
Induces peripheral T-cell tolerance by promoting regulatory T-cell (Treg) activity, shifting the immune response from a Th2 to a Th1/Treg profile, and stimulating the production of allergen-specific IgG4 blocking antibodies that compete with IgE for allergen binding.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Grass pollen allergoid.